Cullinan Oncology (CGEM)

• Market cap: $1.07B
• 1 day: 0.23%
• 5 days: -2.73%
• 1 month: -5.16%
• 3 months: 36.38%
• 6 months: 47.43%
• Year to date: 72.63%
• 1 year: 112.27%
• 5 years: -31.52%
• 10 years: -41.59%
• Sector: Healthcare
• Industry: Biotechnology

About: Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Employees: 109